These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
87 related articles for article (PubMed ID: 12649565)
21. Intraarterial instillation of microencapsulated cells in the pancreatic arteries in pig. Kröger JC; Bergmeister H; Hoffmeyer A; Ceijna M; Karle P; Saller R; Schwendenwein I; von Rombs K; Liebe S; Günzburg WH; Salmons B; Hauenstein K; Losert U; Löhr M Ann N Y Acad Sci; 1999 Jun; 880():374-8. PubMed ID: 10415882 [No Abstract] [Full Text] [Related]
22. Microencapsulated cell-mediated treatment of inoperable pancreatic carcinoma. Löhr M; Hoffmeyer A; Kröger J; Freund M; Hain J; Holle A; Karle P; Knöfel WT; Liebe S; Müller P; Nizze H; Renner M; Saller RM; Wagner T; Hauenstein K; Günzburg WH; Salmons B Lancet; 2001 May; 357(9268):1591-2. PubMed ID: 11377651 [TBL] [Abstract][Full Text] [Related]
23. Ifosfamide metabolism and DNA damage in tumour and peripheral blood lymphocytes of breast cancer patients. Johnstone EC; Lind MJ; Griffin MJ; Boddy AV Cancer Chemother Pharmacol; 2000; 46(6):433-41. PubMed ID: 11138456 [TBL] [Abstract][Full Text] [Related]
24. Use of cell therapy as a means of targeting chemotherapy to inoperable pancreatic cancer. Günzburg WH; Salmons B Acta Biochim Pol; 2005; 52(3):601-7. PubMed ID: 16175235 [TBL] [Abstract][Full Text] [Related]
25. Activated oxazaphosphorines are transported predominantly by erythrocytes. Highley MS; Schrijvers D; Van Oosterom AT; Harper PG; Momerency G; Van Cauwenberghe K; Maes RA; De Bruijn EA; Edelstein MB Ann Oncol; 1997 Nov; 8(11):1139-44. PubMed ID: 9426334 [TBL] [Abstract][Full Text] [Related]
26. [High dose ifosfamide at 15 g/m2/cycle: a feasibility study in 10 patients]. Baranzelli MC; Pichon F; Gourmel B; N'Guyen M; Deligny N; Demaille MC Bull Cancer; 1997 Feb; 84(2):141-6. PubMed ID: 9180836 [TBL] [Abstract][Full Text] [Related]
27. The effect of intra-arterial versus intravenous cisplatinum in the neoadjuvant treatment of osteosarcoma of the limbs: the experience at the Rizzoli Institute. Bacci G; Ferrari S; Forni C; Mercuri M; Picci P; Bertoni F; Capanna R; Manfrini M; Donati D; Brach Del Prever A; Baldini N Chir Organi Mov; 1996; 81(4):369-82. PubMed ID: 9147928 [TBL] [Abstract][Full Text] [Related]
28. Metabolism of ifosfamide to chloroacetaldehyde contributes to antitumor activity in vivo. Börner K; Kisro J; Brüggemann SK; Hagenah W; Peters SO; Wagner T Drug Metab Dispos; 2000 May; 28(5):573-6. PubMed ID: 10772637 [TBL] [Abstract][Full Text] [Related]
29. Renal ontogeny of ifosfamide nephrotoxicity. Aleksa K; Halachmi N; Ito S; Koren G J Lab Clin Med; 2004 Dec; 144(6):285-93. PubMed ID: 15614250 [TBL] [Abstract][Full Text] [Related]
30. Influence of short-term use of dexamethasone on the pharmacokinetics of ifosfamide in patients. Brüggemann SK; Pfäffle S; Peters SO; Wagner T Drug Metab Dispos; 2007 Oct; 35(10):1721-4. PubMed ID: 17600085 [TBL] [Abstract][Full Text] [Related]
31. Characterization and transplantation of agarose microencapsulated canine islets of Langerhans. Tashiro H; Iwata H; Warnock GL; Takagi T; Machida H; Ikada Y; Tsuji T Ann Transplant; 1997; 2(3):33-9. PubMed ID: 9869862 [TBL] [Abstract][Full Text] [Related]
32. High-performance liquid chromatographic-fluorescent method to determine chloroacetaldehyde, a neurotoxic metabolite of the anticancer drug ifosfamide, in plasma and in liver microsomal incubations. Huang Z; Waxman DJ Anal Biochem; 1999 Aug; 273(1):117-25. PubMed ID: 10452807 [TBL] [Abstract][Full Text] [Related]
33. Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. Comandone A; Leone L; Oliva C; Frustaci S; Monteleone M; Colussi AM; Dal Canton O; Bergnolo P; Boglione A; Bumma C J Chemother; 1998 Oct; 10(5):385-93. PubMed ID: 9822357 [TBL] [Abstract][Full Text] [Related]
34. [Gene therapy of pancreatic cancer with microencapsulated CYP2B1-expressing cells]. Löhr M; Faulmann G; Hummel F; Singer MV Onkologie; 2001 Sep; 24 Suppl 5():60-4. PubMed ID: 11600815 [No Abstract] [Full Text] [Related]
35. Indomethacin and pancreatic blood flow. An experimental study in pigs. Hjelmqvist B; Teder H; Borgström A; Björkman S Acta Chir Scand; 1990 Aug; 156(8):543-7. PubMed ID: 2239055 [TBL] [Abstract][Full Text] [Related]
36. Activation of the anticancer prodrugs cyclophosphamide and ifosfamide: identification of cytochrome P450 2B enzymes and site-specific mutants with improved enzyme kinetics. Chen CS; Lin JT; Goss KA; He YA; Halpert JR; Waxman DJ Mol Pharmacol; 2004 May; 65(5):1278-85. PubMed ID: 15102956 [TBL] [Abstract][Full Text] [Related]
37. Introducing ifosfamide in innovative treatment modalities. Dittrich C Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S1-3. PubMed ID: 12042981 [No Abstract] [Full Text] [Related]
38. Pharmacokinetic-stereoselective differentiation of some isomeric analogues of ifosfamide. Sloderbach A; Hładoń B; Sochacki M; Kinas R; Kuśnierczyk H; Laskowska H Pol J Pharmacol; 1997; 49(6):463-9. PubMed ID: 9566050 [TBL] [Abstract][Full Text] [Related]
39. Characterization of a human cell clone expressing cytochrome P450 for safe use in human somatic cell therapy. Günzburg WH; Karle P; Renz R; Salmons B; Renner M Ann N Y Acad Sci; 1999 Jun; 880():326-36. PubMed ID: 10415877 [TBL] [Abstract][Full Text] [Related]
40. Ifosfamide-based drug combinations: preclinical evaluation of drug interactions and translation into the clinic. Vanhoefer U; Schleucher N; Klaassen U; Seeber S; Harstrick A Semin Oncol; 2000 Feb; 27(1 Suppl 1):8-13. PubMed ID: 10697038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]